CD20-mediated apoptosis: signalling through lipid rafts. - Wikidata - awgldk - TriplyDB

CD20-mediated apoptosis: signalling through lipid rafts.

CD20-mediated apoptosis: signalling through lipid rafts.

http://www.wikidata.org/entity/Q34969960

about

New and emerging disease modifying therapies for multiple sclerosis Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics Lipid raft: A floating island of death or survival A cholesterol-dependent CD20 epitope detected by the FMC7 antibody Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance A hybrid protein-polymer nanoworm potentiates apoptosis better than a monoclonal antibody NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.Selective internalization of monoclonal antibodies by B-cell chronic lymphocytic leukaemia cells.Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity Macromolecular therapeutics Separation of liquid phases in giant vesicles of ternary mixtures of phospholipids and cholesterol Microdomains in the membrane landscape shape antigen-presenting cell function.Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives.CD20 antibody primes B lymphocytes for type I interferon production.Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.Synthesis and evaluation of multivalent branched HPMA copolymer-Fab' conjugates targeted to the B-cell antigen CD20.Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.How does B cell depletion therapy work, and how can it be improved?A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab Coiled-coil based drug-free macromolecular therapeutics: in vivo efficacy.Monoclonal antibody therapy of B cell lymphoma.Membrane domains in lymphocytes - from lipid rafts to protein scaffolds.Membrane microdomain sphingolipids are required for anti-CD20-induced death of chronic lymphocytic leukemia B cells.Drug-Free Macromolecular Therapeutics--A New Paradigm in Polymeric Nanomedicines Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab Super-Resolution Imaging and Quantitative Analysis of Membrane Protein/Lipid Raft Clustering Mediated by Cell-Surface Self-Assembly of Hybrid Nanoconjugates Fibroblast growth factor receptor 3 (FGFR3) associated with the CD20 antigen regulates the rituximab-induced proliferation inhibition in B-cell lymphoma cells POLYMERIC BIOMATERIALS AND NANOMEDICINES.B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus.Rituximab in the treatment of peripheral neuropathy associated with monoclonal gammopathy.Sarcospan: a small protein with large potential for Duchenne muscular dystrophy Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children.Functional recombinant extra membrane loop of human CD20, an alternative of the full length CD20 antigen Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions.Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome Cancer therapeutic antibodies come of age: targeting minimal residual disease.Cell surface self-assembly of hybrid nanoconjugates via oligonucleotide hybridization induces apoptosis.Statins do not influence long-term rituximab clinical efficiency in rheumatoid arthritis patients.

P2860

Q22242305-C068E80C-B3B3-4B9E-9340-5B936096D981 Q26849243-960AF22A-3ADD-4CD5-92C5-6413991425C7 Q26998351-11651B53-002E-4473-ACB0-DC5AB2D62871 Q28183678-FC6A8431-0017-4F6C-A5A5-CD3352199AC9 Q28243054-9AA7900B-690B-4607-9E42-3CE373B1F360 Q30420026-CE89EA43-DFF5-481B-85DD-C5471860B7CE Q30440293-F521537D-BBA8-49E7-A4BB-5DCFE5852503 Q30920338-3E40045D-6D4C-473D-8A0F-732951558232 Q33896738-F45F0EEC-CC57-4A5B-B13C-94804FE67952 Q34079574-626E30BB-4347-4805-838E-EBEF4DB8B334 Q34183533-AD8FFEC4-DB01-4997-B984-4F0C8F34F1A8 Q34380974-B3C02BEF-FF2A-45EA-AEEB-64BF07BAB8C3 Q34543066-E41F3632-FBA9-499F-A8FF-09E560A70253 Q34700655-2630C9CE-3FAE-4D25-9D70-2D1D4D6E34C3 Q34846171-0C7911E2-3A47-41ED-9E7A-8B3D9D31DC19 Q34997715-B3E87FA6-FF70-4CF6-A148-A0A79B167F5C Q35104686-DC23B863-4D13-4675-A7C9-775C61EC3C11 Q35567244-CBBDD545-7FED-40E7-8D85-9B144E4A5504 Q35579475-46E4F93E-8E8F-4E92-8AF8-AB7BFB9607C1 Q35633346-D1ADB14A-E2C7-4DD0-A370-7241F19816AE Q35678195-072B46A6-803F-450A-B537-34AE017500E4 Q35684872-30E9D76D-579C-44B4-B5F5-8B5534E7EF2C Q35696789-91E16249-FE83-4467-AE8D-E33EA4C3ECD6 Q35717890-7AE6624F-029A-42B5-B1F6-B50DEF8D1D2B Q35861726-BA4EF742-A6C3-4BFE-BCB2-06AE59C5A3AB Q35911656-49D10D23-6309-4883-B1BF-CBC64E296ACF Q36001159-D61A0EB6-CBD9-434E-890E-D96B63C064A8 Q36347760-73D8A3BE-0483-4C34-B776-B17C0816DE79 Q36376467-42E6C6D8-CC1B-4F64-8BAB-3E183713ADFF Q36577391-C905B54C-DC6C-4578-9910-275FE76BC62A Q36607310-DE7E9CEB-80E5-4A4B-8E15-D98984F7E56A Q36690397-85536BCF-4669-4CDF-A145-FC7FA37FEF11 Q36770915-F4C5CB10-E01B-4B50-AF0B-0B73C565D3D1 Q36777171-AE9D2E7F-540C-48DA-8C78-D445FCDEA378 Q36832106-F8B1C48A-5D58-482D-A8AA-3619ECA797A9 Q36832113-FD8161AF-6F2B-4ABE-8FA8-3FB83F7D394A Q37275486-A4EBC73C-0E6C-4F32-9E4B-3B755DBEB6B7 Q37453793-FFFA142D-A0E9-43E9-970B-EEF922782A2E Q37537969-6AA1CE72-3C4B-4B2E-B13A-50C420A53487 Q37551567-36929B77-E025-4284-A9B6-C6B461A648C8

P2860

CD20-mediated apoptosis: signalling through lipid rafts.

http://www.wikidata.org/entity/Q34969960

description

2002 nî lūn-bûn

@nan

2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

CD20-mediated apoptosis: signalling through lipid rafts.

@ast

CD20-mediated apoptosis: signalling through lipid rafts.

@en

CD20-mediated apoptosis: signalling through lipid rafts.

@nl

type

label

CD20-mediated apoptosis: signalling through lipid rafts.

@ast

CD20-mediated apoptosis: signalling through lipid rafts.

@en

CD20-mediated apoptosis: signalling through lipid rafts.

@nl

prefLabel

CD20-mediated apoptosis: signalling through lipid rafts.

@ast

CD20-mediated apoptosis: signalling through lipid rafts.

@en

CD20-mediated apoptosis: signalling through lipid rafts.

@nl

P1433

Q34969960-840E3733-3A19-4295-873A-EE1F37060BD5

P1476

Q34969960-54ED2932-FCBD-428F-85E3-D9A315F01ECF

P2093

Q34969960-107FD9EE-ABA1-4517-8A75-AC0FED423645

Q34969960-26978731-9CD3-4488-B405-A57C4DD07F5C

Q34969960-7022216F-8577-473B-88D1-B347E4507995

P2860

Q34969960-0269C7E0-C6C1-4149-88CA-3056C15278DA

Q34969960-07FC11AC-9026-4D27-ABED-65BAFAAA8802

Q34969960-1B051B1C-250D-4172-AD23-29DF49CC2F73

Q34969960-2348E73A-E63D-4370-A9E4-651A3B6C4D1D

Q34969960-2378851B-D13E-4E20-A046-AE6105C5B75B

Q34969960-2D8BCA83-1BB5-4FA0-82FB-3D8C3B08EB2F

Q34969960-2E684B91-94D9-4B01-A99C-0EC65F9EEC4D

Q34969960-3218C205-3FA0-40ED-A03B-DF6F2E9DAA75

Q34969960-38C16F39-F338-411C-9C24-D2A4B6692735

Q34969960-3ED947F8-4D05-42A0-9E1B-3F863083970D

P304

Q34969960-F5BA15CA-EAA3-4000-B492-6058714F2023

P31

Q34969960-377B6497-C450-41CB-AB7C-AED8E2628EED

P356

Q34969960-0593B190-E7A0-4FC4-8D9D-B840394B1A2A

P433

Q34969960-D78D18A1-C87F-4E25-8C02-18D874F894B4

P478

Q34969960-033ACE70-B298-4E59-8CFC-6F141369931B

P577

Q34969960-2B9EEBC4-2FDB-405F-B4E4-BD18B22A74B3

P5875

Q34969960-52471DCC-09B6-41BD-BBA8-7C985FD14641

P698

Q34969960-A4B8C24B-D6C0-4B57-B504-B2DF673B485A

P932

Q34969960-BFF75727-EC9A-4874-8B89-788CBAA25B59

P356

J.1365-2567.2002.01495.X

P1433

P1476

CD20-mediated apoptosis: signalling through lipid rafts.

@en

P2093

Haidong Li

http://www.w3.org/2001/XMLSchema#string

Julie P Deans

http://www.w3.org/2001/XMLSchema#string

Maria J Polyak

http://www.w3.org/2001/XMLSchema#string

P2860

Recruitment of CD40 and tumor necrosis factor receptor-associated factors 2 and 3 to membrane microdomains during CD40 signaling

Phosphoprotein associated with glycosphingolipid-enriched microdomains (PAG), a novel ubiquitously expressed transmembrane adaptor protein, binds the protein tyrosine kinase csk and is involved in regulation of T cell activation

CD24 induces apoptosis in human B cells via the glycolipid-enriched membrane domains/rafts-mediated signaling system

Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes

Fc epsilon RI-mediated recruitment of p53/56lyn to detergent-resistant membrane domains accompanies cellular signaling

Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains

Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes

Analysis of two cDNA clones encoding the B lymphocyte antigen CD20 (B1, Bp35), a type III integral membrane protein

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases

P304

176-182

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-2567.2002.01495.X

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P577

2002-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11078071

http://www.w3.org/2001/XMLSchema#string

P698

12383196

http://www.w3.org/2001/XMLSchema#string

P932

1782791

http://www.w3.org/2001/XMLSchema#string